Pfizer’s Strategic Pivot: Seeking External Partner for Promising Cancer Drug
Published on 09/18/2025 at 13:54 | Redaktion boerse-global.deIn a notable strategic shift, Pfizer and its collaborator Arvinas have announced they will seek an external commercialization partner for their experimental breast cancer treatment, vepdegestrant, rather than bringing it to market themselves. This unexpected reversal arrives just ahead of the drug’s anticipated FDA approval in June 2026 and signals a potential move toward significant cost savings for both firms.
The decision centers on a drug that has demonstrated considerable promise in clinical trials. Vepdegestrant successfully delayed the progression of breast cancer in patients with specific mutations by over three months when compared to AstraZeneca’s established therapy, Faslodex. Despite this compelling data, the companies believe a specialized oncology partner could more effectively maximize the drug’s commercial potential. Arvinas described the move as a means to “unlock... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
